Australia's most trusted
source of pharma news
Tuesday, 26 August 2025
Posted 25 August 2025 AM
While most sponsors received a nod for their new PBS listing submissions considered at the PBAC’s mid-year meet, a number of companies have been left in the dark - at least for the time being.
Pharma in Focus analysis of the reimbursement committee’s July meeting outcomes, published on Friday afternoon, show of the 35 new PBS listing submissions considered, 22 were recommended, five were knocked back, five were deferred, and three were marked ‘not applicable’.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.